Leerink cuts Arvinas stock rating post ASCO meeting

Leerink cuts Arvinas stock rating post ASCO meeting#Leerink #cuts #Arvinas #stock #rating #post #ASCO #meeting

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M…

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma…

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment o

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary…

Six Abstracts of Kelun-Biotech's Clinical Studies Published at the 2025 ASCO Annual Meeting

Six Abstracts of Kelun-Biotech's Clinical Studies Published at the 2025 ASCO Annual Meeting#Abstracts #KelunBiotech039s #Clinical #Studies…

Foresee Pharmaceuticals Announces Acceptance of An Abstract for Presentation at ASCO Genitourinary Cancers Symposium 2025

Foresee Pharmaceuticals Announces Acceptance of An Abstract for Presentation at ASCO Genitourinary Cancers Symposium 2025#Foresee #Pharmaceuticals…